Summary table:
Disease | Inheritance | Molecular mechanism |
---|
Monogenic diabetes | Autosomal dominant (primary inheritance pattern) | Activating (GOF) |
Monogenic diabetes | Autosomal recessive (rare) | Partially activating + LOF |
Familial hyperinsulinism | Autosomal recessive (Primary inheritance) | LOF |
Familial hyperinsulinism | Autosomal dominant (less common) | Dominant Negative |
Familial hyperinsulinism (FOCAL) | Paternally inherited LOF variant + loss of maternal allele in pancreatic tissue *a single LOF variant is NOT diagnostic for Focal disease per genereviews, due to potential to miss a maternal variant | |
Katie Russell is a Broad expert on ABCC8 - she shared these slides https://docs.google.com/presentation/d/1Lw5xnS3-EUYBMeSBMQ9euHRG45imqOWDTQ6KRSdGiw8/edit#slide=id.p Her summary -
Image ModifiedCHI
AR - caused by LOF
Some patients with somatic UPD of the pancreas of carriers can develop focal CHI
AD - dominant negative
Did not curate Semidominant monogenic diabetes (MODY) - definitive (GOF / activating mutations by Monogenic diabetes GCEP.); however, there are recessive cases with 1 partially activating and 1 inactivating mutation. This is aka permanent neonatal diabetes. They note that inactivating LOF variants cause hyperinsulinemic hypoglycemia.
Did not curate pulmonary arterial hypertension - not well established per above
Disease | Familial hyperinsulinism, aka congenital hyperinsulinism (CHI), hyperinsulinemic hypoglycemia |
---|
Inheritance | autosomal recessive |
Prevalence | Source: |
Rapid or full curation? | |
ClinGen / GenCC / BabySeq / HGMD / OMIM | Not in ClinGen. GenCC - Definitive Ambry (Semidominant); Strong (Invitae; AR and AD) - no conflicts - sufficent to say there is enough evidence for a strong GDA. |
Clinical Validity Scoring Notes and points | n/a - GenCC provides sufficent evidence that there is a strong association Source: |
Clinical Validity Points Total | Source: |
Clinical Validity Classification Expand |
---|
title | Classifications (pts) |
---|
| Definitive (12pts) Strong (12pts) Moderate (7-11pts) Limited (0.1-6pts) No genetic evidence Refuted Disputed |
| Strong |
Molecular Mechanism Expand |
---|
| Loss of function Gain of function Dominant negative Unknown Other |
| Loss of function NM_000352.3(ABCC8):c.4014G>A(W1338*) - 24932607_Durmaz_2014 Homozygous in patient with congenital hyperinsulinism, diffuse HI determined via histological findings from near-total pancreatecomy at 2 months of age.
M_000352.3(ABCC8):c.3868-1G>A - 23345197_Kapoor_2013 Homozygous in a patient with Congenital hyperinsulism, diffuse HI determined via histological findings from near-total pancreatecomy.
NM_000352.3(ABCC8):c.3509delT(L1170Rfs*38) - 24686051_Demirbilek_2014 Homozygous in patient w/ congenital hyperinsulism HI that responded to octreotide, developmental delay, and ectodermal dysplasia.
KO mouse model 10734066_Seghers_2000 SUR1 knockout mice were generated by inserting a puromycin resistance gene into ABCC8 exon 2. Patch clamp assays were used to show that SUR1-/- mice exhibit no K+ current (Fig 2A) and show spontaneous Ca2+ action potentials (Fig 2B), which recapitulates function data from KATP in patient cells. SUR1-/- mice exhibit mild glucose intolerance in response to glucose challenge (Fig 5) and transient neonatal hypoglycemia (Fig 6), however, the mice do not recapitulate the full human hypoglycemic phenotype.
Focal CHI - |
Penetrance Expand |
---|
| Complete (100%) High (≥80%) Moderate (<80% and >20%) Low (≤20%) |
(list source/PMID) | Source:Incomplete |
Age of Onset Expand |
---|
| Congenital Pediatric Adolescent Adulthood Late adulthood |
(list source/PMID) | |
Severity Expand |
---|
| Embryonic lethal - presence of a pathogenic variant or variants is not compatible with life. The penetrance must be complete. Severe - presence of a pathogenic variant or variant(s) results in significantly reduced fitness. The penetrance must be complete or high. Moderate - significant morbidity or mortality due to clinical features, but fitness may not be reduced, or penetrance is reduced. Mild - Presence of a variant or variant(s) is not associated with reduced fitness, no significant morbidity or mortality, and/or penetrance is low. None - presence of a variant results in no phenotype. An example is recessive disorders in which no phenotype is reported in carriers. |
| |
Clinical Features | inappropriate secretion of insulindespite low blood glucose, which can result in irreversible braindamage if not promptly treated (Helleskov et al., 2017). Thecondition has a variable phenotype usually presenting during the neonatal period or infancy with seizures and/or coma and alarge birth weight due to high levels of insulin acting as a growth factor in utero. (Defranco_2020_32027066) Sources: |
HPO Terms https://hpo.jax.org/app/ | |
Gene SOPs & Notes | |
Curation Summary Expand |
---|
| - The @GENE@ is associated with @inheritance pattern@ @condition@, which is characterized by @clinical features@ (PMIDs). - Variable expression or severity: The severity and expressivity of the disorder is highly variable, even within families. - If multiple conditions associated with the gene: It has also been associated with @inheritance pattern@ @condition@, which is characterized by @clinical features@ (PMIDs). - Limited evidence gene: The PCNA gene has been reported in individuals with early onset autosomal recessive ataxia (PMID: 33426167, 24911150), however, evidence supporting this gene-dIsease relationship is limited |
| The ABCC8 gene is associated with two different diseases with multiple inheritance patterns. Monogenic diabetes, which also includes known as transient or permanent neonatal diabetes of infancy, is primarily an autosomal dominant disorder caused by activating mutations. Autosomal recessive cases with a partially activating mutation and an inactivating mutation have also been reported. It is characterized by the onset of hyperglycemia within the first six months of life with partial or complete insulin deficiency. Clinical manifestations at the time of diagnosis include intrauterine growth restriction, hyperglycemia, glycosuria, osmotic polyuria, severe dehydration, and failure to thrive (PMID: 20301620, 17668386). Familial hyperinsulinism, also known as congenital hyperinsulinism or hyperinsulinemic hypoglycemia, is primarily an autosomal recessive disorder caused by inactivating (loss-of-function; LOF) variants; however, autosomal dominant cases have also been described and is caused by dominant-negative variants (PMID: 32027066, 20301549, 24814349, 26092864). Furthermore, focal hyperinsulinism is also described in individuals with a paternally inherited inactivating (LOF) mutation and loss of the maternal allele in the pancreatic tissue. Familial hyperinsulinism is characterized by hypoglycemia due to an inappropriate secretion of insulin despite low blood glucose. It can range from mild to severe and present from the newborn period to childhood. In the neonatal period or infancy, it can present with seizures and/or coma, as well as large birth weight (PMID: 20301549, 32027066). |
Case ID, Curator name, Date, Jira ticket link | AO 07.26.24, 47230812301136 |
Disease | Familial hyperinsulinism, aka congenital hyperinsulinism (CHI), hyperinsulinemic hypoglycemia |
---|
Inheritance | autosomal dominant |
Prevalence | |
Rapid or full curation? | |
ClinGen / GenCC / BabySeq / HGMD / OMIM | Not in ClinGen. GenCC: Definitive for Semidominant hyperinsulinemic hypoglycemia, familial, 1 by Ambry Definitive for AD hyperinsulinemic hypoglycemia, familial, 1 by Illumina Strong for AD hyperinsulinemic hypoglycemia, familial, 1 by Invitae
|
Clinical Validity Scoring Notes |
LINK if SOP is a long document. Short notes if it is easy to digest. eg. Last known truncating variant | and points | n/a - not needed, no conflicts in GenCC |
Clinical Validity Points Total | n/a - not needed, no conflicts in GenCC |
Clinical Validity Classification Expand |
---|
title | Classifications (pts) |
---|
| Definitive (12pts) Strong (12pts) Moderate (7-11pts) Limited (0.1-6pts) No genetic evidence Refuted Disputed |
| Definitive based on GenCC submissions |
Molecular Mechanism Expand |
---|
| Loss of function Gain of function Dominant negative Unknown Other |
| Dominant-negative Saint-Martin 2015 PMID: 24814349 De novo variants include Leu511M, L891P is de novo, L1390P, Asn1481Ile, Asp1506Glu, Ile1512Ser. Nine missense (L511M, E825K, K890T, L891P, G1379S, A1459V, N1481I, D1506E, I1512S) ABCC8 mutations were subjected to in vitro expression studies testing traffic efficiency and responses of mutant channels to activation by MgADP and diazoxide. Eight of the 9 missense mutations exhibited normal trafficking (all except G1379S). Seven of the 8 mutants reaching the plasma membrane had dramatically reduced response to MgADP or to diazoxide(<10% of wild-type response) - all except K890T. Expression levels normal, but reduced response - supports dominant negative effect.
Nessa 2015 PMID: 26092864 7 different dominant variants described, unresponsive to diazoxide treatment 3 variants (D1506E, M1514K, A113V) were co-expressed with WT to investigate a dominant negative effect. 2 experiments performed - 6Rb+ flux and whole-cell patch-clamp. In both of these assays, all the mutants tested impaired the DZX-activated currents but the degree of the effect varied between mutants. However, in all cases it reduced flux and current by over 50% (Fig. 6).
Huopio 2000 11018078 |
Penetrance Expand |
---|
| Complete (100%) High (≥80%) Moderate (<80% and >20%) Low (≤20%) |
(list source/PMID) | |
Age of Onset Expand |
---|
| Congenital Pediatric Adolescent Adulthood Late adulthood |
(list source/PMID) | |
Severity Expand |
---|
| Embryonic lethal - presence of a pathogenic variant or variants is not compatible with life. The penetrance must be complete. Severe - presence of a pathogenic variant or variant(s) results in significantly reduced fitness. The penetrance must be complete or high. Moderate - significant morbidity or mortality due to clinical features, but fitness may not be reduced, or penetrance is reduced. Mild - Presence of a variant or variant(s) is not associated with reduced fitness, no significant morbidity or mortality, and/or penetrance is low. None - presence of a variant results in no phenotype. An example is recessive disorders in which no phenotype is reported in carriers. |
| |
Clinical Features | Same as AR CHI |
HPO Terms https://hpo.jax.org/app/ | |
Gene SOPs & Notes | |
Curation Summary |
- - The severity and expressivity of the disorder is highly variable, even within families.
|
|
- It has also been associated with @inheritance pattern@ @condition@, which is characterized by @clinical features@ (PMIDs).
|
|
- Limited evidence gene: The PCNA gene has been reported in individuals with early onset autosomal recessive ataxia (PMID: 33426167, 24911150), however, evidence supporting this gene-dIsease relationship is limited
|
| See above under AR CHI |
Case ID, Curator name, Date, Jira ticket link | AO 07.26.24 |